# Integer Holdings Corp: Form 10-Q for the period ended Sep 30, 2016

- Company: [Integer Holdings Corp](/companies/itgr.md) (CIK 1114483)
- Form: 10-Q
- Filed: 2016-11-08
- Accepted by EDGAR: Nov 8, 2016, 15:03 ET
- Period: 2016-09-30
- Accession: 0001114483-16-000044
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1114483/000111448316000044/itgr-2016093010q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1114483/000111448316000044/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2016-07-02 to 2016-09-30 | $346.6m | us-gaap:SalesRevenueNet |
| Revenue | 9 months, 2016-01-02 to 2016-09-30 | $1.03bn | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2016-07-02 to 2016-09-30 | $248.7m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2016-01-02 to 2016-09-30 | $741.8m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2016-07-02 to 2016-09-30 | $97.9m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2016-01-02 to 2016-09-30 | $285.4m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2016-07-02 to 2016-09-30 | $36.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2016-01-02 to 2016-09-30 | $115.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2016-07-02 to 2016-09-30 | $36.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2016-01-02 to 2016-09-30 | $77.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2016-07-02 to 2016-09-30 | $27.9m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2016-01-02 to 2016-09-30 | $83.4m | us-gaap:InterestExpense |
| Income tax | 3 months, 2016-07-02 to 2016-09-30 | −$2.7m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2016-01-02 to 2016-09-30 | −$1.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2016-07-02 to 2016-09-30 | $11.5m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2016-01-02 to 2016-09-30 | −$2.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2016-07-02 to 2016-09-30 | $0.37 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2016-01-02 to 2016-09-30 | −$0.06 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2016-07-02 to 2016-09-30 | $0.37 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2016-01-02 to 2016-09-30 | −$0.06 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2016-07-02 to 2016-09-30 | 31,153,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2016-01-02 to 2016-09-30 | 30,756,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2016-01-02 to 2016-09-30 | $71.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2016-01-02 to 2016-09-30 | $47.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2016-09-30 | $45.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-09-30 | $525.1m | us-gaap:AssetsCurrent |
| Total assets | at 2016-09-30 | $2.88bn | us-gaap:Assets |
| Current liabilities | at 2016-09-30 | $199.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2016-09-30 | $2.14bn | us-gaap:Liabilities |
| Long-term debt | at 2016-09-30 | $1.72bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2016-09-30 | $29.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2016-09-30 | $741.0m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 74,518 characters.

*This Quarterly Report on Form 10-Q should be read in conjunction with the disclosures included in our Annual Report on Form 10-K for the fiscal year ended January 1, 2016. In addition, please read this section in conjunction with our Condensed Consolidated Financial Statements and Notes to Condensed Consolidated Financial Statements contained herein.*

### Forward-Looking Statements

Some of the statements contained in this report and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations, and these statements are subject to known and unknown risks, uncertainties and assumptions. Forward-looking statements include statements relating to:

- future sales, expenses, and profitability;
- future development and expected growth of our business and industry;
- our ability to execute our business model and our business strategy;
- our ability to identify trends within our industries and to offer products and services that meet the changing needs of those markets;
- our ability to remain in compliance with the financial covenants contained in the agreement governing our Senior Secured Credit Facilities; and
- projected capital expenditures.

You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or “variations” or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this report. Except as required by applicable law, we are under no duty to update any of these forward-looking statements after the date of this report or to conform these statements to actual results.

It is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results. Some of these factors include the following: our high level of indebtedness following the acquisition of Lake Region Medical, our inability to pay principal and interest on this high level of outstanding indebtedness, or to remaining in compliance with financial and other covenants under our senior secured credit facilities, and the risk that this high level of indebtedness limits our ability to invest in our business and overall financial flexibility; our dependence upon a limited number of customers; customer ordering patterns; product obsolescence; our inability to market current or future products; pricing pressure from customers; our ability to timely and successfully implement cost and capital reduction, synergy, and plant consolidation initiatives; our reliance on third party suppliers for raw materials, products and subcomponents; fluctuating operating results; our inability to maintain high quality standards for our products; challenges to our intellectual property rights; product liability claims; product field actions or recalls; our inability to successfully consummate and integrate acquisitions, including the acquisition of Lake Region Medical, and to realize synergies and benefits from these acquisitions and to operate these acquired businesses in accordance with expectations; our unsuccessful expansion into new markets; our failure to develop new products including system and device products; the timing, progress and ultimate success of pending regulatory actions and approvals; our inability to obtain licenses to key technology; regulatory changes, including Health Care Reform, or consolidation in the healthcare industry; global economic factors including currency exchange rates and interest rates; the resolution of various legal and environmental actions brought against the Company; and other risks and uncertainties that arise from time to time and are described in Item 1A “Risk Factors” of our Annual Report on Form 10-K and in other periodic filings with the SEC. Except as required by applicable law, the Company assumes no obligation to update forward-looking statements in this report whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.

- 35 -

### Our Business

Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device outsource (“MDO”) manufacturers in the world serving the cardiac, neuromodulation, orthopedics, vascular, advanced surgical, and power solutions markets. We provide innovative, high quality medical technologies that seek to enhance the lives of patients worldwide. During the fourth quarter of 2015, we acquired all of the outstanding common stock of Lake Region Medical Holdings, Inc. (“Lake Region Medical”). As a result, we have three reportable segments: Greatbatch Medical, QiG Group (“QiG”), and Lake Region Medical. In March 2016, we spun-off of a portion of our QiG segment (the “Spin-off”), which is now an independent publicly traded company known as Nuvectra Corporation (“Nuvectra”). As a result of the Lake Region Medical acquisition and the Spin-off, we are in the process of re-evaluating our internal management and financial reporting structure, which may change our product line and segment reporting in the future. This process is expected to be finalized in 2016. See Note 2 “Divestiture and Acquisition” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for further description of these transactions and Note 15 “Business Segment, Geographic and Concentration Risk Information” for further information on our product lines and business segments.

Effective June 30, 2016, we changed our name from Greatbatch, Inc. (“Greatbatch”) to Integer Holdings Corporation. The new name represents the union of the Greatbatch Medical, Lake Region Medical and Electrochem brands. Integer, meaning whole or complete, signifies our more comprehensive products and service offerings, and a new dimension in our combined capabilities. When used in this report, the terms “Integer,” “we,” “us,” “our” and the “Company” mean Integer Holdings Corporation and its subsidiaries.

The Greatbatch Medical segment designs and manufactures products where we either own the intellectual property or have unique manufacturing and assembly expertise. These products include medical devices and components for the cardiac, neuromodulation, orthopedics, portable medical, vascular and energy markets among others. The Greatbatch Medical segment also offers value-added assembly and design engineering services for medical devices that utilize its component products.

The QiG segment focuses on the design and development of complete medical device systems and components for our customers. After completion of the Spin-off, the operations of QiG primarily consists of Centro de Construcción de Cardioestimuladores del Uruguay (“CCC”), which was acquired in 2014. QiG seeks to assist customers in accelerating the velocity of innovation while delivering an optimized supply chain and critical cost efficiencies. The medical devices QiG designs and develops are full product solutions that utilize the medical technology expertise and capabilities residing within Greatbatch Medical and Lake Region Medical. QiG revenue consists primarily of sales of various medical device products such as implantable pulse generators, programmer systems, battery chargers, patient wands and leads to medical device companies. Once the medical devices developed by QiG reaches significant production levels, the responsibility for manufacturing these products may be transferred to Greatbatch Medical.

The Lake Region Medical segment specializes in the design, development, and manufacturing of products across the medical component and device spectrum, primarily serving the cardio, vascular and advanced surgical markets. Lake Region Medical offers fully integrated outsourced manufacturing, regulatory and engineering services, contract manufacturing, finished device assembly services, original device development, and supply chain management.

### Our Acquisitions

On October 27, 2015, we acquired all of the outstanding common stock of Lake Region Medical, headquartered in Wilmington, MA. Lake Region Medical is a manufacturer of interventional and diagnostic wire-formed medical devices and components specializing in minimally invasive devices for cardiovascular, endovascular, and neurovascular applications. This acquisition has added scale and diversity to our operations, which has enhanced customer access and experience by providing a more comprehensive portfolio of technologies. The operating results of Lake Region Medical are included in our Lake Region Medical segment from the date of acquisition. The aggregate purchase price of Lake Region Medical including debt assumed was $1.77 billion, which was funded primarily through new senior secured credit facilities and the issuance of senior notes. Total assets acquired from Lake Region Medical were $2.1 billion. Total liabilities assumed from Lake Region Medical were $1.3 billion. For the first nine months of 2016, Lake Region Medical added approximately $607.1 million to our revenue and decreased our net loss by approximately $27.9 million.

With the acquisition of Lake Region Medical, our main strategic priorities over the next two to three years include, among others, the integration of both legacy companies, driving integration synergies, and the paying down our outstanding debt.

- 36 -

As previously mentioned, we expect to finalize the process of re-evaluating our internal management and financial reporting structure during 2016. As a result of this process, we may change our product line and/or segment reporting. If we change our segment reporting, we will assess goodwill for impairment and re-allocate our goodwill to the new reporting units based on their relative fair value at that time. While the results of our annual impairment reviews have historically not indicated impairment, impairment reviews are highly dependent on management’s projections of our future operating results and cash flows, discount rates based on the Company’s weighted average cost of capital, the Company’s stock price, revenue and adjusted EBITDA multiples, and appropriate benchmark peer companies. Assumptions used in determining future operating results and cash flows include current and expected market conditions, and future sales and earnings forecasts, which incorporate projected future operating efficiencies. Subsequent changes in these assumptions and estimates could result in future impairment charges. Any impairment charges that we record in the future could negatively impact our results of operations and financial condition. A detailed discussion of our impairment testing is included in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Our Critical Accounting Estimates” in our Annual Report on Form 10-K. Despite our lower than expected revenue and adjusted EBITDA, and reduction in our stock price during 2016, we believe that no impairment of goodwill or intangible assets was indicated for any of our reporting units as of September 30, 2016. This determination was based upon management’s evaluation, which took into consideration our current and expected results to date, current revenue and adjusted EBITDA multiples, and the significant cushion that existed as of the last goodwill impairment analysis. However, there can be no assurances that our goodwill and/or intangible assets will not be impaired in future periods if future operating results and cash flows continue to deteriorate, are less than our projections, and/or we continue to have a sustained decrease in our stock price.

### Our Customers

Our products are designed to provide reliable, long-lasting solutions that meet the evolving requirements and needs of our customers. The nature and extent of our selling relationships with each customer are different in terms of breadth of products purchased, purchased product volumes, length of contractual commitment, ordering patterns, inventory management, and selling prices.

Our Greatbatch Medical and Lake Region Medical customers include large multinational original equipment manufacturers (“OEMs”) and their subsidiaries, such as Abbott Laboratories, Biotronik, Boehringer Ingelheim, Boston Scientific, Halliburton Company, Johnson & Johnson, LivaNova, Medtronic, Nevro Corp., Philips Healthcare, Smith & Nephew, St. Jude Medical, Stryker, and Zimmer Biomet. For the nine months ended September 30, 2016, Johnson & Johnson, Medtronic, and St. Jude Medical collectively accounted for 46% of our total sales. QiG customers include various early stage medical device companies.

### Financial Overview

For the third quarter and first nine months of 2016, sales increased $199.9 million, or 136%, and $544.3 million, or 113%, respectively, in comparison to the prior year periods. Included in these periods is $203.9 million and $607.1 million of sales contributed by Lake Region Medical, respectively. Sales for the first nine months of 2016 also include the impact of foreign currency exchange rate fluctuations, which reduced Greatbatch Medical sales by approximately $1 million in comparison to the prior year due to the strengthening dollar versus the Euro. Foreign currency exchange rate fluctuations did not materially impact Greatbatch Medical sales for the third quarter of 2016. Excluding the impact of these items, our organic constant currency sales decreased 4% and 13% for the third quarter and first nine months of 2016 in comparison to the prior year, respectively. These decreases were primarily due to 1) the reduction of shipments in a limited number of cardiac rhythm management (“CRM”) customer programs; 2) the decline in energy market-driven revenue; and 3) a decline due to contractual price reductions. These decreases were partially offset by growth in sales to our neuromodulation customers during the first half of 2016. Lake Region Medical revenues were consistent with the prior year for the quarter and year-to-date periods.

- 37 -

### Use of Non-GAAP Financial Information

We prepare our condensed consolidated financial statements in accordance with generally accepted accounting principles in the United States of America (“GAAP”). Additionally, we consistently report and discuss in our earnings releases and investor presentations adjusted net income, adjusted earnings per diluted share, earnings before interest, taxes, depreciation, and amortization (“EBITDA”), adjusted EBITDA and organic constant currency sales growth rates. Adjusted net income and adjusted earnings per diluted share consist of GAAP amounts adjusted for the following to the extent occurring during the period: (i) acquisition-related charges, (ii) amortization of intangible assets, (iii) facility consolidation, optimization, manufacturing transfer and system integration charges, (iv) asset write-down and disposition charges, (v) charges in connection with corporate realignments or a reduction in force, (vi) certain litigation expenses, charges and gains, (vii) unusual or infrequently occurring items, (viii) gain/loss on cost and equity method investments, (ix) the income tax (benefit) related to these adjustments and (x) certain tax items related to the Federal research and development tax credit which are outside the normal benefit received for the period. Adjusted earnings per diluted share are calculated by dividing adjusted net income by diluted weighted average shares outstanding. Adjusted EBITDA consists of GAAP net income (loss) plus (i) the same adjustments as listed above except for items (ix), and (x), (ii) GAAP stock-based compensation, interest expense, and depreciation, (iii) GAAP provision (benefit) for income taxes and (iv) cash gains received from cost and equity method investments during the period. To calculate organic constant currency sales growth rates, which exclude the impact of changes in foreign currency exchange rates, as well as the impact of any acquisitions or divestitures of product lines on sales growth rates, we convert current period sales from local currency to U.S. dollars using the previous periods’ foreign currency exchange rates and exclude the amount of sales acquired/divested during the period from the current/previous period amounts, respectively. We believe that the presentation of adjusted net income, adjusted diluted earnings per share, EBITDA, adjusted EBITDA, and organic constant currency sales growth rates provides important supplemental information to management and investors seeking to understand the financial and business trends relating to our financial condition and results of operations. Additionally, incentive compensation targets for our executives and associates are based upon these adjusted measures.

A reconciliation of GAAP net income (loss) and diluted earnings (loss) per share (“EPS”) to adjusted amounts is as follows (in thousands, except per share amounts):

|  | Three Months Ended September 30, 2016 Pre-Tax | Net Income | Per Diluted Share | October 2, 2015 Pre-Tax | Net Income | Per Diluted Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Income and diluted EPS as reported (GAAP) | $8,717 | $11,458 | $0.37 | $6 | $22 | $— |
| Adjustments: |  |  |  |  |  |  |
| Amortization of intangibles(a) | 9,473 | 6,702 | 0.22 | 3,243 | 2,271 | 0.09 |
| IP related litigation (SG&A)(a)(b) | 499 | 324 | 0.01 | 1,127 | 733 | 0.03 |
| Consolidation and optimization expenses (OOE)(a)(c) | 7,779 | 6,409 | 0.21 | 5,473 | 4,523 | 0.17 |
| Acquisition and integration expenses (OOE)(a)(d) | 5,319 | 3,492 | 0.11 | 5,202 | 4,845 | 0.18 |
| Asset dispositions, severance and other (OOE)(a)(e) | 272 | 36 | — | 3,169 | 2,468 | 0.09 |
| Lake Region Medical transaction costs (interest expense)(a)(f) | — | — | — | 4,788 | 3,112 | 0.12 |
| Loss (gain) on cost and equity method investments, net (other expense (income), net)(a) | 245 | 159 | 0.01 | (4,579) | (2,976) | (0.11) |
| Tax adjustments(g) | — | (2,784) | (0.09) | — | 400 | 0.02 |
| Taxes(a) | (6,508) | — | — | (3,031) | — | — |
| Adjusted net income and diluted EPS (Non-GAAP)(h) | $25,796 | $25,796 | $0.83 | $15,398 | $15,398 | $0.58 |
| Adjusted effective tax rate/diluted weighted average shares (a) | 20.1% | 31,153 |  | 16.4% | 26,441 |  |

- 38 -

### MANAGEMENT'S DISCUSSION AND ANALYSIS

|  | Nine Months Ended September 30, 2016 Pre-Tax | Net Income | Per Diluted Share | October 2, 2015 Pre-Tax | Net Income | Per Diluted Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Income (loss) and diluted EPS as reported (GAAP) | $(3,358) | $(1,972) | $(0.06) | $21,761 | $17,313 | $0.66 |
| Adjustments: |  |  |  |  |  |  |
| Amortization of intangibles(a) | 28,451 | 20,125 | 0.64 | 10,008 | 6,996 | 0.27 |
| IP related litigation (SG&A)(a)(b) | 2,691 | 1,749 | 0.06 | 3,286 | 2,136 | 0.08 |
| Consolidation and optimization expenses (OOE)(a)(c) | 21,804 | 17,698 | 0.57 | 19,202 | 15,422 | 0.58 |
| Acquisition and integration expenses (OOE)(a)(d) | 23,143 | 15,148 | 0.49 | 5,366 | 4,961 | 0.19 |
| Asset dispositions, severance and other (OOE)(a)(e) | 5,057 | 4,459 | 0.14 | 4,881 | 3,600 | 0.14 |
| Lake Region Medical transaction costs (interest expense)(a)(f) | — | — | — | 4,788 | 3,112 | 0.12 |
| Gain on cost and equity method investments, net (other expense (income), net)(a) | (932) | (606) | (0.02) | (5,119) | (3,327) | (0.13) |
| Tax adjustments(g) | — | (2,784) | (0.09) | — | 1,200 | 0.05 |
| Taxes(a) | (23,039) | — | — | (12,760) | — | — |
| Adjusted net income and diluted EPS (Non-GAAP)(h) | $53,817 | $53,817 | $1.72 | $51,413 | $51,413 | $1.95 |
| Adjusted effective tax rate/diluted weighted average shares (a)(i) | 30.0% | 31,211 |  | 19.9% | 26,372 |  |

(a) The difference between pre-tax and net income (loss) amounts is the estimated tax impact related to the respective adjustment. Net income amounts are computed using a 35% U.S., Mexico, Germany, and France statutory tax rate, a 0% Swiss tax rate, a 20% Netherlands statutory tax rate, a 25% Uruguay statutory tax rate, and a 12.5% Ireland statutory tax rate. Expenses that are not deductible for tax purposes (i.e. permanent tax differences) are added back at 100%.

(b) In 2013, we filed suit against AVX Corporation alleging they were infringing our intellectual property. Given the complexity and significant costs incurred pursuing this litigation, we are excluding these litigation expenses from adjusted amounts. This matter proceeded to trial during the first quarter of 2016 and a federal jury awarded the Company $37.5 million in damages. To date, no gains have been recognized in connection with this litigation.

(c) During 2016 and 2015, we incurred costs primarily related to the transfer of our Beaverton, OR portable medical and Plymouth, MN vascular manufacturing operations to Tijuana, Mexico. Additionally, with the acquisition of Lake Region Medical, 2016 costs also include expenses incurred in connection with the closure of Lake Region Medical’s Arvada, CO, site and the consolidation of its two Galway, Ireland sites, which was initiated by Lake Region Medical in 2014.

(d) During 2016 and 2015, we incurred acquisition and integration costs related to the acquisition of Lake Region Medical, which was acquired in October 2015. During 2015, we incurred costs related to the integration of CCC Medical Devices, which was acquired in August 2014.

(e) Costs consist primarily of legal and professional fees incurred in connection with the Spin-off, which was completed in March 2016.

(f) During the third quarter of 2015, we recorded transaction costs (i.e. debt commitment fees, interest rate swap termination costs) in connection with our acquisition of Lake Region Medical.

(g) Tax adjustments for the 2016 periods include a discrete tax benefit related to certain transaction costs of the Lake Region Medical acquisition and the Spin-off. For the 2015 periods, tax adjustments consist of the 2015 Federal R&D tax credit, which was enacted during the fourth quarter of 2015 and has been permanently reinstated. Amounts assume that the tax credit was effective at the beginning of the year for 2015.

(h) The per share data in this table have been rounded to the nearest $0.01 and therefore may not sum to the total.

(i) Adjusted diluted weighted average shares for the year-to-date 2016 period includes 455,000 of potentially dilutive shares not included in the computation of diluted weighted average common shares for GAAP diluted EPS purposes because their effect would have been anti-dilutive given our net loss during that period.

- 39 -

GAAP diluted EPS for the third quarter and first nine months of 2016 was income of $0.37 per share and a loss of $0.06 per share, respectively, compared to $0.00 and income of $0.66 per share, respectively for the comparable 2015 periods. Adjusted diluted EPS of $0.83 and $1.72 per share for the third quarter and first nine months of 2016, respectively, increased 43% and decreased 12%, respectively, in comparison to the prior year periods. The primary drivers behind these variances are as follows:

- GAAP and adjusted diluted EPS for the third quarter and nine month periods of 2016 includes $29.9 million and $78.5 million, respectively, of operating income added from Lake Region Medical;
- The organic constant currency decline in sales as discussed above;
- A $7.0 million and $13.5 million increase in operating income (primarily lower SG&A and RD&E Costs) for the quarter and nine month period comparisons, respectively, due to the Spin-off;
- The third quarter and nine month periods of 2016 includes the benefit of approximately $11 million and $25 million, respectively, of synergies realized in connection with our acquisition of Lake Region Medical;
- A $22.0 million and $75.2 million increase in interest expense for the third quarter and nine month period comparisons, respectively, due to the debt incurred in connection with the Lake Region Medical acquisition in October 2015;
- The third quarter and nine month period 2016 GAAP effective tax rate includes $2.9 million and $1.6 million, respectively, of net discrete tax benefits related to Lake Region Medical and Spin-off transaction costs, which are added back for adjusted diluted EPS purposes;
- The addition of 5 million shares of common stock issued in connection with the Lake Region Medical acquisition; and
- The decrease in GAAP diluted EPS for the nine month period was also attributable to a $20.6 million increase in acquisition, integration and Spin-off related expenses over the comparable 2015 period, which are included in GAAP results, but are excluded from adjusted amounts.

A reconciliation of net income (loss) as reported (GAAP) to EBITDA and adjusted EBITDA is as follows (dollars in thousands):

|  | Three Months Ended September 30, 2016 | October 2, 2015 | Nine Months Ended September 30, 2016 | October 2, 2015 |
| --- | ---: | ---: | ---: | ---: |
| Net income (loss) as reported (GAAP) | $11,458 | $22 | $(1,972) | $17,313 |
| Interest expense | 27,870 | 5,825 | 83,395 | 8,151 |
| Provision (benefit) for income taxes | (2,741) | (16) | (1,386) | 4,448 |
| Depreciation | 12,893 | 5,504 | 38,963 | 16,933 |
| Amortization | 9,473 | 3,243 | 28,451 | 10,008 |
| EBITDA (Non-GAAP) | 58,953 | 14,578 | 147,451 | 56,853 |
| IP related litigation | 499 | 1,127 | 2,691 | 3,286 |
| Stock-based compensation expense | 1,950 | 3,027 | 5,773 | 8,999 |
| Consolidation and optimization expenses | 7,779 | 5,473 | 21,804 | 19,202 |
| Acquisition and integration expenses | 5,319 | 5,202 | 23,143 | 5,366 |
| Asset dispositions, severance and other | 272 | 3,169 | 5,057 | 4,881 |
| Noncash (gain) loss on cost and equity method investments | 245 | (1,178) | (270) | (1,718) |
| Adjusted EBITDA (Non-GAAP) | $75,017 | $31,398 | $205,649 | $96,869 |
| Adjusted EBITDA as a % of sales (Non-GAAP) | 21.6% | 21.4% | 20.0% | 20.1% |

The primary driver behind the increases in adjusted EBITDA for the third quarter and first nine months of 2016 versus the comparable 2015 periods was approximately $48 million and $136 million, respectively, of adjusted EBITDA added from Lake Region Medical, partially offset by lower sales and gross profit from legacy Greatbatch Medical during the same periods as discussed above. Additionally, the Spin-off of Nuvectra accounted for approximately $7 million and $13 million of the increase in our adjusted EBITDA for the third quarter and nine month periods, respectively.

- 40 -

As of the end of the 2016 third quarter, we are in compliance with the financial covenants of our senior secured credit facilities. We are actively monitoring our financial covenant compliance and based upon our current expectations for our 2016 adjusted EBITDA, as defined in the agreement governing our Senior Secured Credit Facilities, there is a potential that we will not be able to meet our minimum interest coverage ratio at year-end 2016. We are working with the administrative agent under the agreement governing our Senior Secured Credit Facilities to obtain an amendment or waiver of our financial covenants before year-end. If a waiver or amendment cannot be obtained from our lenders, an event of default may occur. An event of default under our debt agreements may result in the acceleration of our indebtedness. As a result, management believes that compliance with these covenants is material to us. See the “Liquidity and Capital Resources” section of this Item for further discussion on our debt covenants and liquidity.

### Financial Outlook

Our current full-year 2016 outlook is as follows (in millions, except for per share amounts):

|  | GAAP High | Low | Adjusted Comparable Basis High | Low |
| --- | ---: | ---: | ---: | ---: |
| Revenue | $1,396 | $1,376 | $1,395 | $1,375 |
| Net Income | $13 | $9 | $86 | $82 |
| Earnings per Diluted Share | $0.42 | $0.27 | $2.75 | $2.60 |
| EBITDA | N/A | N/A | $295 | $285 |

Adjusted Comparable Basis net income and EPS for 2016 are expected to consist of GAAP net income and EPS, excluding items such as intangible amortization (approximately $40 million), IP related litigation costs, and consolidation, acquisition, integration, and asset disposition/write-down charges totaling approximately $105 million. The after-tax impact of these items is estimated to be approximately $70 million, or approximately $2.25 per diluted share. Additionally, our comparable basis revenue, adjusted effective tax rate, adjusted net income, adjusted diluted EPS and adjusted EBITDA guidance excludes the results of Nuvectra prior to its spin-off on March 14, 2016, of $1.2 million, a tax benefit of $1.4 million, a loss of $2.6 million, a loss of $0.08 per share, and $3.7 million of adjusted EBITDA, respectively.

With respect to our expectations under “Financial Outlook” above, for adjusted comparable basis net income, adjusted comparable basis earnings per diluted share, and adjusted comparable basis EBITDA, except as described above, further reconciliations by line item to the closest corresponding GAAP financial measures are not available without unreasonable efforts on a forward-looking basis due to the high variability, complexity and visibility with respect to charges excluded from these non-GAAP financial measures.

### Our CEO’s View

Our third quarter results demonstrate that the steps we have taken are beginning to stabilize our business. Our focus on reducing costs, improving working capital, and business process optimization is progressing well and has allowed us to stem the revenue and adjusted EBITDA declines we saw during the first half of the year. Our outlook for the remainder of the year further demonstrates this business stabilization. With that said, we acknowledge that we have work to do in order to further stabilize our business and bring us back to predictable revenue growth.

We believe there is a significant opportunity to expand and grow our business. Today, a relatively low percentage of medical device manufacturing is outsourced, and the market is highly fragmented. Our competencies in manufacturing, core technologies, quality control, and operational excellence will allow our customers to leverage significant benefits provided by Integer. As we work closely with our customers, and deepen those relationships, we feel we have established a better line of sight to our customer’s programs, demand plans and growth objectives, which will help us better manage our business and product line forecasts. Integer’s value proposition remains intact and we believe we are well-positioned within the medical technology market, with a broad suite of technologies, capabilities and product offerings to deliver innovative, cost-effective solutions to our customers in order to enrich the lives of patients worldwide.

- 41 -

### Product Development

#### Greatbatch Medical and Lake Region Medical

We believe our core business is well positioned because our OEM customers are able to leverage our portfolio of intellectual property, and we continue to build a healthy pipeline of diverse medical technology opportunities. The combination with Lake Region Medical brought together two highly complementary organizations that we believe can provide a new level of industry leading capabilities and services to OEM customers while building value for our stockholders. Through this transformative deal, we believe we are at the forefront of innovating technologies and products that help change the face of healthcare, providing our customers with a distinct advantage as they bring complete systems and solutions to market. In turn, our customers will be able to accelerate patient access to life enhancing therapies. We believe that the combined company will be able to offer a substantially more comprehensive portfolio of products and services to our customers utilizing the best technologies, providing a single point of support, and driving optimal outcomes. Additionally, by combining the capabilities of both Greatbatch Medical and Lake Region Medical, we now have a full suite of device-level competencies that allow us to innovate across our product categories. Some of the more significant product development opportunities Greatbatch Medical and Lake Region Medical are pursuing are as follows:

| Product Line | Product Development Opportunities |
| --- | --- |
| Advanced Surgical, Orthopedics, and Portable Medical | Developing a portfolio of single use products and instruments for the orthopedics market. |
|  | Developing a portfolio of wireless products for the portable medical and orthopedic markets. |
| Cardio and Vascular | Developing a portfolio of catheter, wire-based, sensor and coating products for the cardio and vascular markets. |
| Cardiac/Neuromodulation | Developing next generation technology programs including the Gen 2 QHR battery, next generation filtered feedthroughs, high voltage capacitors and vertically integrated lead solutions. |
| Electrochem | Developing power solutions to advance performance and reliability of battery packs in critical environments. |

#### QiG

Through QiG, we can develop or assist our customers in developing complete medical devices. After completion of the Spin-off, our design and development of complete medical device systems is being facilitated by our combined teams in Greatbatch Medical, Lake Region Medical, and CCC. We are now able to more broadly partner with medical device companies, leveraging Greatbatch Medical’s and Lake Region Medical’s discrete technology and design and manufacturing expertise for core components, as well as the capabilities of CCC regarding full devices, which we believe will enhance our medical device innovation efforts.

- 42 -

### Cost Savings and Consolidation Efforts

In 2016 and 2015, we recorded charges in other operating expenses, net related to various cost savings and consolidation initiatives. These initiatives were undertaken to improve our operational efficiencies and profitability, the most significant of which are as follows (dollars in millions):

| Initiative | Expected Expense | Expected Capital | Expected Benefit to Operating Income(a) | Expected Completion |
| --- | --- | --- | --- | --- |
| 2014 investments in capacity and capabilities | $46 - $52 | $25 - $28 | \> $20 | 2017 |
| Orthopedic facilities optimization | $45 - $48 | $31 - $35 | $15 - $20 | 2017 |
| Lake Region Medical consolidations | $20 - $25 | $5 - $6 | $12 - $13 | 2018 |

(a) Represents the annual benefit to our operating income expected to be realized from these initiatives through cost savings and/or increased capacity. These benefits will be phased in over time as the various initiatives are completed, and some of which are already included in our current period results.

See Note 9 “Other Operating Expenses, Net” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about the timing, cash flow impact and amount of future expenditures for these initiatives. We continually evaluate our operating structure in order to maximize efficiencies and drive margin expansion. Future charges are expected to be incurred as a result of the consolidation and optimization of the combined Greatbatch Medical and Lake Region Medical businesses. We seek to create an optimized manufacturing footprint, leveraging our increased scale and product capabilities while also supporting the needs of our customers. Our efforts will include:

- potential manufacturing consolidations;
- continuous improvement;
- productivity initiatives;
- direct material and indirect expense savings opportunities; and
- the establishment of centers of excellence around the world.

In September 2016, we announced the planned closure and transfer of product lines of our Clarence, NY facility. We will be transferring these machined component product lines to other Integer locations in the U.S. The project is expected to take 12 to 18 months and will generate estimated annual synergies of approximately $4 million starting in 2018.

For 2016, we expect to achieve between $30 million to $35 million in net synergies in connection with our acquisition of Lake Region Medical, which exceeds our $25 million annual net synergies target. These net synergies are expected to increase to $60 million by 2018. We expect the investment necessary to achieve these synergies to be approximately $60 million to $75 million, which consists of $20 million to $25 million in capital expenditures and $40 million to $50 million of operating expenses over a period of three years following completion of the acquisition.

### Our Financial Results

We utilize a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31. For 52-week years, each quarter contains 13 weeks. The third quarter and first nine months of 2016 and 2015 ended on September 30, and October 2, respectively, and each contained 13 weeks and 39 weeks, respectively.

In connection with our acquisition of Lake Region Medical, we have recast our revenue by product line into the following four categories:

- Cardio and Vascular - Includes the legacy Greatbatch Vascular product line sales plus the legacy Lake Region Medical Cardio and Vascular product line sales less the legacy Lake Region Medical Cardiac/Neuromodulation sales.
- Cardiac/Neuromodulation - Includes the legacy Greatbatch Cardiac/Neuromodulation and QiG sales plus the legacy Lake Region Medical Cardiac/Neuromodulation sales previously included in their Cardio and Vascular product line sales.
- Advanced Surgical, Orthopedics, and Portable Medical - Includes legacy Greatbatch Orthopedics and Portable Medical product line sales plus the legacy Lake Region Medical Advanced Surgical product line sales.
- Electrochem - Includes the legacy Greatbatch Energy, Military and Environmental product line sales.

We are currently in the process of re-evaluating our internal management and financial reporting structure, which may change our product line and segment reporting in the future. This process is expected to be finalized in 2016.

- 43 -

The following tables present certain selected financial information derived from our Condensed Consolidated Financial Statements for the periods presented (dollars in thousands, except per share):

| Sales: | Three Months Ended September 30, 2016 | October 2, 2015 | Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| Cardio and Vascular | $148,273 | $14,107 | $134,166 | N/A |
| Cardiac/Neuromodulation | 95,781 | 75,577 | 20,204 | 27% |
| Advanced Surgical, Orthopedics, and Portable Medical | 95,190 | 44,976 | 50,214 | 112% |
| Electrochem | 8,870 | 11,977 | (3,107) | (26)% |
| Elimination of interproduct line sales | (1,547) | — | (1,547) | N/A |
| Total Sales | 346,567 | 146,637 | 199,930 | 136% |
| Cost of sales | 248,658 | 94,991 | 153,667 | 162% |
| Gross profit | 97,909 | 51,646 | 46,263 | 90% |
| Gross profit as a % of sales | 28.3% | 35.2% |  |  |
| Selling, general and administrative expenses (“SG&A”) | 36,265 | 22,308 | 13,957 | 63% |
| SG&A as a % of sales | 10.5% | 15.2% |  |  |
| Research, development and engineering costs, net (“RD&E”) | 11,412 | 14,299 | (2,887) | (20)% |
| RD&E as a % of sales | 3.3% | 9.8% |  |  |
| Other operating expenses, net | 13,370 | 13,844 | (474) | (3)% |
| Operating income | 36,862 | 1,195 | 35,667 | N/A |
| Operating margin | 10.6% | 0.8% |  |  |
| Interest expense, net | 27,870 | 5,825 | 22,045 | 378% |
| Other expense (income), net | 275 | (4,636) | 4,911 | N/A |
| Income before benefit for income taxes | 8,717 | 6 | 8,711 | N/A |
| Benefit for income taxes | (2,741) | (16) | (2,725) | N/A |
| Effective tax rate | (31.4)% | N/A |  |  |
| Net income | $11,458 | $22 | $11,436 | N/A |
| Net margin | 3.3% | —% |  |  |
| Diluted earnings per share | $0.37 | $— | $0.37 | N/A |

- 44 -

### MANAGEMENT'S DISCUSSION AND ANALYSIS

| Sales: | Nine Months Ended September 30, 2016 | October 2, 2015 | Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| Cardio and Vascular | $426,142 | $37,370 | $388,772 | N/A |
| Cardiac/Neuromodulation | 284,479 | 248,450 | 36,029 | 15% |
| Advanced Surgical, Orthopedics, and Portable Medical | 290,836 | 150,795 | 140,041 | 93% |
| Electrochem | 30,361 | 46,232 | (15,871) | (34)% |
| Elimination of interproduct line sales | (4,631) | — | (4,631) | N/A |
| Total Sales | 1,027,187 | 482,847 | 544,340 | 113% |
| Cost of sales | 741,779 | 320,852 | 420,927 | 131% |
| Gross profit | 285,408 | 161,995 | 123,413 | 76% |
| Gross profit as a % of sales | 27.8% | 33.5% |  |  |
| SG&A | 115,781 | 69,021 | 46,760 | 68% |
| SG&A as a % of sales | 11.3% | 14.3% |  |  |
| RD&E | 42,358 | 39,907 | 2,451 | 6% |
| RD&E as a % of sales | 4.1% | 8.3% |  |  |
| Other operating expenses, net | 50,004 | 29,449 | 20,555 | 70% |
| Operating income | 77,265 | 23,618 | 53,647 | 227% |
| Operating margin | 7.5% | 4.9% |  |  |
| Interest expense, net | 83,395 | 8,151 | 75,244 | N/A |
| Other income, net | (2,772) | (6,294) | 3,522 | (56)% |
| Income (loss) before provision (benefit) for income taxes | (3,358) | 21,761 | (25,119) | N/A |
| Provision (benefit) for income taxes | (1,386) | 4,448 | (5,834) | (131)% |
| Effective tax rate | 41.3% | 20.4% |  |  |
| Net income (loss) | $(1,972) | $17,313 | $(19,285) | (111)% |
| Net margin | (0.2)% | 3.6% |  |  |
| Diluted earnings (loss) per share | $(0.06) | $0.66 | $(0.72) | (109)% |

### Product Line Sales Highlights

For the third quarter and first nine months of 2016, Cardio and Vascular sales increased $134.2 million and $388.8 million, respectively, versus the comparable 2015 periods. These increases were primarily attributable to the acquisition of Lake Region Medical, which added approximately $136 million and $394 million, respectively, of revenue to this product line. Foreign currency exchange rates did not have a material impact on sales in comparison to the prior year. On an organic constant currency basis, which comparison disregards revenue provided by Lake Region Medical, Cardio and Vascular sales for the third quarter and first nine months of 2016 decreased 10% and 13%, respectively, primarily due to specific customers’ working down their inventory levels.

For the third quarter and first nine months of 2016, Cardiac/Neuromodulation sales increased $20.2 million and $36.0 million, respectively, versus the comparable 2015 periods. The Lake Region Medical acquisition added approximately $16 million and $53 million of revenue to this product line, respectively. Foreign currency exchange rates did not have a material impact on sales in comparison to the prior year. On an organic constant currency basis, third quarter and first nine months of 2016 Cardiac/Neuromodulation sales increased 4% and decreased 8%, respectively. Cardiac/Neuromodulation sales for the first nine months of 2016 were negatively impacted by reduced shipments in a limited number of CRM customer programs, resulting in lower orders compared to the prior year, and contractual price reductions. These impacts were driven by both internal and external delays in product launches, customer clinical market share changes, customers lowering inventory levels, and order disruption due to acquisition-related influences in the medical technology markets. These factors were partially offset by growth in sales to neuromodulation customers in the first half of 2016. Cardiac/Neuromodulation sales stabilized during the third quarter of 2016, as the impact of certain CRM customer programs, which negatively impacted the first half of 2016, began to subside. We believe that the challenges we faced during the first half of the year in this product line are now behind us.

- 45 -

For the third quarter and first nine months of 2016, Advanced Surgical, Orthopedics, and Portable Medical sales increased $50.2 million and $140.0 million, respectively, versus the comparable 2015 periods. This increase was primarily attributable to the acquisition of Lake Region Medical, which added approximately $54 million and $163 million, respectively, of revenue to this product line. Foreign currency exchange rates had a negative $1 million impact on legacy Greatbatch Medical sales for this product line in comparison to the prior year nine month period. Foreign currency exchange rate fluctuations did not materially impact legacy Greatbatch Medical sales for this product line for the third quarter of 2016. On an organic constant currency basis, third quarter and first nine months of 2016 Advanced Surgical, Orthopedics, and Portable Medical sales decreased 8% and 15%, respectively, which was primarily due to portable medical customers building safety stock in the fourth quarter of 2015 in anticipation of our product line transfers, thus lowering orders in the first quarter of 2016, a backlog in shipments to one specific Portable Medical customer, and price concessions made in return for long-term volume commitments. As we look to 2017, we see slight revenue growth opportunities driven by new product launches and acceleration in targeted areas.

For the third quarter and first nine months of 2016, Electrochem sales declined 26% and 34%, respectively, versus the comparable 2015 periods. Foreign currency exchange rates did not materially impact this product line during the quarter and the Lake Region Medical acquisition did not add any revenue to this product line. Our Electrochem product line continues to trend with the health of the oil and gas market. Although we have seen revenue declines throughout the first nine months of 2016, primarily driven by the prolonged downturn in the energy market, our customers are indicating that they believe the market has bottomed out and there are signs of a slow recovery. Electrochem volumes with our military and environmental customers remain stable. As the market has contracted, we have been able to advance our competitive position with key strategic customers resulting in multi-year supply agreements and the opportunity to quote on significant new business opportunities. We are actively pursuing new customer and market opportunities, developing new product solutions and investing in R&D to advance our technology. As we manage the Electrochem product line through this challenging revenue period, we are rationalizing our cost structure and maintaining inventory at appropriate levels to improve our return on invested capital.

### Gross Profit

Changes to gross profit as a percentage of sales (“Gross Margin”) from the prior year were due to the following:

|  | Change From Prior Year Three Months | Nine Months |
| --- | ---: | ---: |
| Impact of Lake Region Medical(a) | (3.1)% | (3.3)% |
| Production efficiencies, volume and mix(b) | (3.6)% | (3.4)% |
| Performance-based compensation(c) | 1.7% | 1.2% |
| Price(d) | (2.4)% | (2.0)% |
| Other | 0.5% | 1.8% |
| Total percentage point change to gross profit as a percentage of sales | (6.9)% | (5.7)% |

(a) Amount represents the impact to our Gross Margin related to Lake Region Medical, which was acquired in October 2015 and historically had lower Gross Margins than Greatbatch Medical.

(b) Our Gross Margin for 2016 has been negatively impacted by lower production volumes, as well as a higher mix of sales of lower margin products partially offset by production efficiencies gained as a result of our investments in capacity and capabilities.

(c) Amount represents the change in performance-based compensation versus the prior year and is recorded based upon the actual results achieved.

(d) Our Gross Margin for 2016 has been negatively impacted by price concessions given to our larger OEM customers in return for long-term volume commitments.

- 46 -

### SG&A Expenses

Changes to SG&A expenses from the prior year were due to the following (in thousands):

|  | Change From Prior Year Three Months | Nine Months |
| --- | ---: | ---: |
| Performance-based compensation(a) | $(1,099) | $(1,374) |
| Legal fees(b) | (665) | (1,245) |
| Nuvectra SG&A(c) | (3,914) | (6,277) |
| Impact of Lake Region Medical acquisition(d) | 16,256 | 52,609 |
| Other(e) | 3,379 | 3,047 |
| Net increase in SG&A | $13,957 | $46,760 |

(a) Amounts represent the change in performance-based compensation versus the prior year period and is recorded based upon actual results achieved.

(b) Amounts represent the change in legal costs compared to the prior year period and includes IP related defense costs, as well as other corporate initiatives. In 2013, we filed suit against one of our cardiac/neuromodulation competitors alleging they were infringing on our IP. In January 2016, a jury returned a verdict finding in favor of Integer and awarded us $37.5 million in damages. The finding is subject to post-trial proceedings, including a possible appeal by our competitor. We have not recorded any gains in connection with this litigation as no cash has been received. Costs associated with this litigation accounted for approximately $0.6 million of the quarter over quarter and year over year decreases in SG&A expenses from 2015 to 2016 as the trial for this litigation concluded in the first quarter of 2016.

(c) Amounts represent the decrease in SG&A costs attributable to Nuvectra, which was spun-off in March 2016.

(d) Amounts represent the incremental SG&A expenses from Lake Region Medical, which was acquired in October 2015. Note that the three and nine month amounts are approximately $20 million and $70 million, respectively, below the prior year Lake Region Medical amounts on a pro forma basis reflecting the synergies realized in connection with the acquisition.

(e) Amounts represent the net impact of various increases and decreases to SG&A costs and include the impact of normal increases in operating costs as well as increased costs associated with operating a Company that is nearly double the size of a year ago.

### RD&E Expenses, Net

Net RD&E expenses are comprised of the following (in thousands):

|  | Three Months Ended September 30, 2016 | October 2, 2015 | Nine Months Ended September 30, 2016 | October 2, 2015 |
| --- | ---: | ---: | ---: | ---: |
| Research, development and engineering costs | $13,376 | $15,551 | $46,754 | $44,654 |
| Less: cost reimbursements | (1,964) | (1,252) | (4,396) | (4,747) |
| Total RD&E, net | $11,412 | $14,299 | $42,358 | $39,907 |

Net RD&E expenses for the 2016 third quarter decreased $2.9 million versus the comparable 2015 period as $0.7 million of higher customer cost reimbursements and $4.1 million less RD&E expenses as a result of the Spin-off was partially offset by $2.8 million of additional RD&E expenses from Lake Region Medical. For the nine months ended September 30, 2016, net RD&E expenses increased $2.5 million versus the comparable 2015 period primarily due to $9.1 million of net RD&E costs added from Lake Region Medical, as well as $0.4 million of lower customer cost reimbursements, which were partially offset by a $8.9 million decrease in RD&E as a result of the Spin-off. The remainder of the year to date increase was attributable to an increased level of research and development investments in order to support organic growth initiatives including development opportunities in the Neurostimulation, Structural Heart, Neuro Vascular and Peripheral Vascular markets, which are expected to generate future revenues over the longer-term.

- 47 -

### Other Operating Expenses, Net

Other Operating Expenses, Net is comprised of the following (in thousands):

|  | Three Months Ended September 30, 2016 | October 2, 2015 | Nine Months Ended September 30, 2016 | October 2, 2015 |
| --- | ---: | ---: | ---: | ---: |
| 2014 investments in capacity and capabilities(a) | $4,542 | $5,116 | $13,821 | $17,854 |
| Orthopedic facilities optimization(a) | 329 | 357 | 628 | 1,348 |
| Lake Region Medical consolidations(a) | 2,908 | — | 7,355 | — |
| Acquisition and integration costs(b) | 5,319 | 5,202 | 23,143 | 5,366 |
| Asset dispositions, severance and other(c) | 272 | 3,169 | 5,057 | 4,881 |
| Total other operating expenses, net | $13,370 | $13,844 | $50,004 | $29,449 |

(a) Refer to “Cost Savings and Consolidation Efforts” section of this Item and Note 9 “Other Operating Expenses, Net” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for disclosures related to the timing and level of remaining expenditures for these initiatives.

(b) During the third quarter and first nine months of 2016, we incurred $5.2 million and $18.9 million, respectively, in Lake Region Medical integration costs, which primarily included professional, consulting, severance, retention, relocation, and travel costs. Additionally, during the third quarter and first nine months of 2016, we incurred $0.2 million and $4.2 million, respectively, in transaction costs related to the acquisition of Lake Region Medical, which primarily included change-in-control payments to former Lake Region Medical executives, as well as professional and consulting fees. We incurred $5.1 million in similar costs during the third quarter and first nine months of 2015. Refer to Note 9 “Other Operating Expenses, Net” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for disclosures related to the timing and level of remaining expenditures for acquisition and integration costs.

(c) During the first nine months of 2016 and 2015, we incurred legal and professional costs in connection with the Spin-off of Nuvectra of $4.4 million ($0.02 million in the third quarter of 2016) and $4.6 million ($3.1 million in the third quarter of 2015), respectively. Refer to Note 2 “Divestiture and Acquisition” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional discussion on the Spin-off.

We continually evaluate our operating structure in order to maximize efficiencies and drive margin expansion. Other Operating Expenses, Net for 2016 are expected to be approximately $55 million to $65 million.

### Interest Expense

Interest expense for the third quarter of 2016 was $27.9 million compared to $5.8 million for the third quarter of 2015. For the nine months ended September 30, 2016, interest expense totaled $83.4 million compared to $8.2 million for the same period in 2015. These increases were primarily due to $1.76 billion of debt borrowed in connection with the Lake Region Medical acquisition and $55.0 million borrowed in connection with the Spin-off. See Note 6 “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information pertaining to our debt.

- 48 -

### Other Expense (Income), Net

Other Expense (Income), Net for the first nine months of 2016 and 2015 includes income realized on our cost and equity method investments of $0.9 million ($0.2 million loss for the third quarter of 2016) and $5.1 million ($4.6 million gain for the third quarter of 2015), respectively. As of September 30, 2016, we had $24.4 million of investments in equity and other cost method securities. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest our investment may not be recoverable. These investments are in start-up research and development companies whose fair value is highly subjective in nature and could be subject to significant fluctuations in the future that could result in material gains or losses.

Other Expense (Income), Net also includes the impact of foreign currency exchange rate fluctuations on transactions denominated in foreign currencies, which decreased (less income) $0.2 million and increased (more income) $0.3 million during the third quarter and first nine months of 2016, respectively, compared to the same periods of 2015. Going forward, we expect the impact of foreign currency exposures could be more significant to our consolidated results versus historical levels given the inclusion of Lake Region Medical’s foreign operations, which increased our exposure to foreign currencies, primarily the Euro, Mexican Peso and Malaysian Ringgit. See Item 3 “Quantitative and Qualitative Disclosures About Market Risk” of this report for disclosures related to our most significant foreign currency exposures.

### Provision for Income Taxes

The GAAP effective tax rate for the first nine months of 2016 was 41.3% on $3.4 million of losses before the benefit for income taxes compared to 20.4% on $21.8 million of income before the provision for income taxes for the same period of 2015. The GAAP effective tax rate for the first nine months of 2016 includes the impact of a $1.6 million ($2.9 million for the third quarter of 2016) of net discrete tax benefits related to Lake Region Medical and Spin-off transaction costs. The three and nine month periods of 2015 do not include the benefit of the Federal R&D tax credit, which was enacted during the fourth quarter of 2015 and has been permanently reinstated. For fiscal year 2016, the GAAP effective tax rate is expected to be approximately (30%). The GAAP tax benefit for the third quarter and expected tax benefit for full year 2016 is due to the Company having projected losses in higher tax rate jurisdictions and income in lower tax rate jurisdictions.

Excluding the impact of the above items, our adjusted effective tax rate for the first nine months of 2016 was 30.0%. For the full year, our adjusted effective tax rate is expected to be approximately 25% to 30%. This decrease is primarily attributable to the Company tax affecting its non-GAAP adjustments at the statutory rate, consistent with its adjusted diluted EPS methodology, but at the lower expected full-year effective tax rate for GAAP purposes as required. The impact from these differences is expected to reverse in the fourth quarter of 2016. Cash taxes are expected to be approximately $8 million for 2016.

We expect there to be continued volatility of this effective tax rate due to several factors, including the impact of the Lake Region Medical acquisition, changes in the mix of pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations. We continuously evaluate and currently have various tax planning initiatives in place that are aimed at reducing our effective tax rate over the long-term.

- 49 -

### Government Regulation

The Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act (collectively “Health Care Reform”) legislated broad-based changes to the U.S. healthcare system that could significantly impact our business operations and financial results, including higher or lower revenue, as well as higher employee medical costs and taxes. Health Care Reform imposes significant new taxes on medical device OEMs, which are expected to result in a significant increase in the tax burden on our industry and which could have a material negative impact on our financial condition, results of operations and our cash flows. Beginning on January 1, 2016, the medical device excise tax was suspended through December 31, 2017, but if this suspension is not continued or made permanent thereafter, the medical device excise tax will be automatically reinstated starting on January 1, 2018. Other elements of Health Care Reform, such as comparative effectiveness research, an independent payment advisory board, payment system reforms including shared savings pilots and other provisions, could meaningfully change the way healthcare is developed and delivered, and may materially impact numerous aspects of our business, results of operations and financial condition. Many significant parts of Health Care Reform will be phased in over the next several years and require further guidance and clarification in the form of regulations.

In the first quarter of 2014, we initiated a voluntary field corrective action for all Standard Offset Cup Impactors after an internal review determined that the sterilization recommendation in the instructions for use for the product did not meet requirements for sterility assurance, which has the potential to result in surgical infection. We have validated two sterilization parameters that meet acceptable sterility assurance levels and provided them to affected customers. We have informed the FDA and other government agencies of this action, which impacts all Standard Offset Cup Impactors manufactured and distributed from 2004 to 2013. We have received three complaints possibly related to this issue, however no adverse events have been reported.

We do not expect customer complaints, voluntary field corrective actions, or negative regulatory actions will have a material effect on our consolidated results of operations, financial position, or cash flows. However, there can be no assurance that any customer complaints, voluntary field corrective actions, or negative regulatory actions regarding our products, that may arise in the future or that which we currently believe to be immaterial, do not have a material effect on our results of operations, financial position or cash flows in the future.

### Liquidity and Capital Resources

*(Dollars in thousands)*

|  | As of September 30, 2016 | January 1, 2016 |
| --- | ---: | ---: |
| Cash and cash equivalents | $44,995 | $82,478 |
| Working capital | $325,248 | $360,764 |
| Current ratio | 2.63 | 2.69 |

The decrease in cash and cash equivalents, working capital, and current ratio from the end of 2015 were primarily due to the $76.3 million of cash divested with the Spin-off, which was funded with cash on hand as well as $55.0 million of borrowings on our revolving line of credit. Additionally, cash flows from operating activities for the first nine months of 2016 were $71.8 million, which were used to fund property, plant and equipment purchases of $47.0 million, as well as the repayment of $28.8 million on our outstanding term loans. Of the $45.0 million of cash and cash equivalents on hand as of September 30, 2016, $18.2 million is being held at our foreign subsidiaries and is considered permanently reinvested.

***Credit Facilities –*** As of September 30, 2016, we had senior secured credit facilities (the “Senior Secured Credit Facilities”) that consists of (i) a $200 million revolving credit facility (the “Revolving Credit Facility”), which had $50 million drawn as of September 30, 2016, (ii) a $361 million term loan A facility (the “TLA Facility”), and (iii) a $1,017 million term loan B facility (the “TLB Facility”). Additionally, as of September 30, 2016, we had $360 million aggregate principal amount of 9.125% senior notes due on November 1, 2023 (the “Senior Notes”) outstanding. The Revolving Credit Facility will mature on October 27, 2020, the TLA Facility will mature on October 27, 2021 and the TLB Facility will mature on October 27, 2022. The TLB facility was issued at a 1% discount. The Senior Secured Credit Facilities include mandatory prepayments customary for credit facilities of its nature.

- 50 -

The Revolving Credit Facility and TLA Facility contain financial covenants requiring (A) a maximum total net leverage ratio (as defined in the agreement governing the Senior Secured Credit Facilities) of 6.5:1.00, subject to step downs beginning in the fourth quarter of 2016 and (B) a minimum interest coverage ratio of adjusted EBITDA (as defined in the Senior Secured Credit Facilities) to interest expense of 3.00:1.00. As of September 30, 2016, our total net leverage ratio, calculated in accordance with our credit agreement, was approximately 5.55 to 1.00. For the twelve month period ended September 30, 2016, our ratio of adjusted EBITDA to interest expense, calculated in accordance with our credit agreement, was approximately 3.11 to 1.00. Failure to comply with these financial covenants would result in an event of default as defined under the Revolving Credit Facility and TLA Facility unless a waiver is received from these lenders. An event of default under the Revolving Credit Facility and TLA Facility may result in the acceleration of our indebtedness. As a result, management believes that compliance with these covenants is material to us. As of September 30, 2016, we were in full compliance with the financial covenants described above. We are actively monitoring our financial covenant compliance and based upon our current expectations for our 2016 adjusted EBITDA, as defined in the agreement governing the Senior Secured Credit Facilities, there is a potential that we will not be able to meet our minimum interest coverage ratio at year-end 2016. We are working with the administrative agent under our credit facilities to obtain an amendment or waiver of our financial covenants before year-end. If a waiver or amendment cannot be obtained from our lenders, an event of default may occur.

The Revolving Credit Facility is supported by a consortium of thirteen banks with no bank controlling more than 27% of the facility. As of September 30, 2016, the banks supporting 88% of the Revolving Credit Facility each had an S&P credit rating of at BBB+ or better, which is considered investment grade. The banks which support the remaining 12% of the Revolving Credit Facility are not currently being rated.

See Note 6 “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for a further description on the Company’s outstanding debt.

### Summary of Cash Flows

*(in thousands)*

| Cash provided by (used in): | Nine Months Ended September 30, 2016 | October 2, 2015 |
| --- | ---: | ---: |
| Operating activities | $71,799 | $30,985 |
| Investing activities | (50,885) | (36,875) |
| Financing activities | (58,865) | (1,830) |
| Effect of foreign currency exchange rates on cash and cash equivalents | 468 | (510) |
| Net change in cash and cash equivalents | $(37,483) | $(8,230) |

***Operating Activities –*** The $40.8 million increase was due to a $26.9 million increase in cash flow provided by working capital and a $26.9 million increase in cash net income. The cash flow from working capital accounts primarily related to a $25.0 million decrease in inventory in comparison to the prior year. One of our key strategic priorities is to reduce our working capital levels, and in particular inventory levels, to improve our cash conversion cycle. Additionally, we have successfully extended payment terms with many key supply chain partners, which should also improve our cash conversion cycle. These initiatives are expected to improve our working capital levels by $25 million to $50 million by the end of 2016.

***Investing Activities –*** The $14.0 million increase in net cash used was primarily attributable to higher levels of cash used in 2016 for the purchase of property, plant, and equipment in connection with the consolidation and optimization initiatives discussed in Note 9 “Other Operating Expenses, Net” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report, as well as an increased level of routine capital expenditures as a result of the Lake Region Medical acquisition. Our current expectation is that capital spending for 2016 will be in the range of $55 million to $60 million, of which approximately half is discretionary in nature. We anticipate that cash on hand, cash flows from operations and available borrowing capacity under our Revolving Credit Facility will be sufficient to fund these capital expenditures.

***Financing Activities –*** The $57.0 million increase in net cash used consisted primarily of $76.3 million of cash that was divested with the Spin-off, partially offset by a $28.3 million net increase in our debt obligations. Additionally, during the first nine months of 2016 we paid $6.8 million to purchase the remaining non-controlling interests in QiG’s Algostim and PelviStim subsidiaries, which were included as part of the Spin-off. See Note 2 “Divestiture and Acquisition” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for a further description of the Spin-off.

- 51 -

***Capital Structure –*** As of September 30, 2016, our capital structure consists of $1.8 billion of debt outstanding under our Senior Secured Credit Facilities and Senior Notes and 30.8 million shares of common stock outstanding. If necessary, we currently have access to $141.1 million under our Revolving Credit Facility. This amount may vary from period to period based upon our debt and EBITDA levels, which impacts the covenant calculations discussed above. If necessary, we are also authorized to issue 100 million shares of common stock and 100 million shares of preferred stock. As of September 30, 2016, our debt service obligations, comprised of principal and interest for the remainder of 2016, are estimated to be approximately $33 million.

Based on current expectations, we believe that our projected cash flows provided by operations, available cash and cash equivalents and potential borrowings under the Revolving Credit Facility should be sufficient to meet our working capital and fixed capital requirements for the next twelve months. If our future financing needs increase, we may need to arrange additional debt or equity financing. Accordingly, we evaluate and consider from time to time various financing alternatives to supplement our financial resources. However, we cannot be assured that we will be able to enter into any such arrangements on acceptable terms or at all. We have clear line of sight to the Lake Region Medical acquisition synergies and believe we will be able to de-lever the Company to 3.5X to 3X adjusted EBITDA, as defined in the agreement governing the Senior Secured Credit Facilities, over the next two to three years.

***Non-Guarantor Information –*** For the nine months ended September 30, 2016, after giving pro forma effect to the completion of the Spin-off, our subsidiaries that are non-Guarantors under our Senior Secured Credit Facilities represented approximately 30% and 41% of our revenue and EBITDA, respectively. In addition, as of September 30, 2016, after giving pro forma effect to the completion of the Spin-off, our subsidiaries that are non-Guarantors under our Senior Secured Credit Facilities held approximately 27% of our total tangible assets and 3% of our total tangible liabilities. Tangible assets consist of total assets less intangible assets, intercompany receivables, and deferred taxes. Tangible liabilities consist of total liabilities less intercompany payables and deferred taxes.

### Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements within the meaning of Item 303(a)(4) of Regulation S-K.

### Impact of Recently Issued Accounting Standards

In the normal course of business, we evaluate all new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), SEC, Emerging Issues Task Force (“EITF”) or other authoritative accounting bodies to determine the potential impact they may have on our Condensed Consolidated Financial Statements. See Note 16 “Impact of Recently Issued Accounting Standards” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about these recently issued accounting standards and their potential impact on our financial condition or results of operations.

### Contractual Obligations

A table of our contractual obligations as of January 1, 2016 was included in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K for the fiscal year ended January 1, 2016. There have been no significant changes to our contractual obligations during the nine months ended September 30, 2016. See Note 6 “Debt” and Note 11 “Commitments and Contingencies” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for further discussion on our contractual obligations.

### Critical Accounting Policies and Estimates

The preparation of our Condensed Consolidated Financial Statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. Our estimates, assumptions and judgments are based on historical experience and various other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amount of assets and liabilities that are not readily apparent from other sources. Making estimates, assumptions and judgments about future events is inherently unpredictable and is subject to significant uncertainties, some of which are beyond our control. Management believes the estimates, assumptions and judgments employed and resulting balances reported in the Condensed Consolidated Financial Statements are reasonable; however, actual results could differ materially.

There have been no significant changes to the critical accounting policies and estimates as compared to those disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K.

- 52 -

## Market risk

As filed, 6,415 characters.

***Foreign Currency –*** As of September 30, 2016, we have foreign operations in Ireland, Germany, France, Switzerland, Mexico, Uruguay, and Malaysia, which expose us to foreign currency exchange rate fluctuations due to transactions denominated in Euros, Swiss francs, Mexican pesos, Uruguayan pesos, and Malaysian ringgits. We continuously evaluate our foreign currency risk, and we use operational hedges, as well as forward currency exchange rate contracts, to manage the impact of currency exchange rate fluctuations on earnings and cash flows. We do not enter into currency exchange rate derivative instruments for speculative purposes. A hypothetical 10% change in the value of the U.S. dollar in relation to our most significant foreign currency exposures would have had an impact of approximately $12 million on our annual sales. This amount is not indicative of the hypothetical net earnings impact due to partially offsetting impacts on cost of sales and operating expenses in those currencies. We estimate that foreign currency exchange rate fluctuations during the nine months ended September 30, 2016 decreased sales in comparison to the 2015 period by approximately $1 million.

We have historically entered into forward contracts to purchase Mexican pesos in order to hedge the risk of peso-denominated payments associated with our operations in Mexico. These forward contracts are accounted for as cash flow hedges. The amounts recorded during the nine months ended September 30, 2016 and October 2, 2015 related to our forward contracts was an increase in Cost of Sales of $2.3 million and $1.2 million, respectively. No portion of the change in fair value of our foreign currency exchange rate contracts during the nine months ended September 30, 2016 and October 2, 2015 was considered ineffective. As of September 30, 2016, our outstanding contracts had a negative fair value of $1.4 million. See Note 11 “Commitments and Contingencies” to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information regarding our outstanding forward contracts.

We translate all assets and liabilities of our foreign operations, where the U.S. dollar is not the functional currency, at the period-end exchange rate and translate sales and expenses at the average exchange rates in effect during the period. The net effect of these translation adjustments is recorded in the Condensed Consolidated Financial Statements as Comprehensive Income (Loss). The translation adjustment for the first nine months of 2016 and 2015 was a gain of $12.3 million and a loss of $1.5 million, respectively. Translation adjustments are not adjusted for income taxes as they relate to permanent investments in our foreign subsidiaries. Net foreign currency gains and losses included in Other Expense (Income), Net amounted to a gain of $1.8 million and $1.6 million for the first nine months of 2016 and 2015, respectively. A hypothetical 10% change in the value of the U.S. dollar in relation to the Euro, our most significant foreign currency net asset exposure, would have had an impact of approximately $44 million on our foreign net assets as of September 30, 2016.

***Interest Rates –*** Historically, we have entered into interest rate swap agreements in order to hedge against potential changes in cash flows on our outstanding variable rate debt. As a result of the Lake Region Medical acquisition, the forecasted cash flows that our interest rate swaps were hedging were no longer expected to occur. Accordingly, during the fourth quarter of 2015, we terminated our outstanding interest rate swap agreements at that time.

On June 20, 2016, we entered into a three-year $200 million interest rate swap with an effective date of June 27, 2017 to hedge against potential changes in cash flows on our outstanding variable rate debt, which are also indexed to the one-month LIBOR rate. Under the terms of the swap agreement, we will receive a floating interest rate indexed to the one-month LIBOR rate and pay a fixed interest rate of 1.1325%. The variable rate received on the interest swap and the variable rate paid on the outstanding borrowings will have the same rate of interest, excluding the credit spread, and will reset and pay interest on the same date. The swap is being accounted for as a cash flow hedge. As of September 30, 2016, this swap has a negative fair value of $1.0 million.

On July 7, 2016, we entered into an additional one-year $250 million interest rate swap with an effective date of July 27, 2016 to hedge against potential changes in cash flows on outstanding borrowings under our outstanding variable rate debt. The swap will terminate on July 27, 2017. Under the terms of the swap agreement, the Company will pay a fixed interest rate of 0.615% and receive a floating interest rate equal to the one-month LIBOR rate. The variable rate received on the interest swap and the variable rate paid on the outstanding borrowings will have the same rate of interest, excluding the credit spread, and will reset and pay interest on the same date. The swap is being accounted for as a cash flow hedge. As of September 30, 2016, this swap has a positive fair value of $0.1 million.

- 53 -

As of September 30, 2016, we had $1.8 billion in principal outstanding on our debt, of which $360 million related to our Senior Notes which has a fixed interest rate of 9.125%, $361 million related to our TLA Facility and $50 million related to our Revolving Credit Facility, which both have a variable interest rate, and $1,017 million related to our TLB Facility which has a 1.00% LIBOR floor, and as such, has a variable interest rate when LIBOR is above 1.00%. Interest rates on our TLA Facility, TLB Facility, and Revolving Credit Facility reset, at our option, based upon the prime rate or LIBOR rate, thus subjecting us to interest rate risk. We continuously evaluate our interest rate exposures and may take steps to mitigate these exposures as appropriate. Refer to Note 6 “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about our outstanding debt. A hypothetical one percentage point (100 basis points) increase in the LIBOR rate on the $1.2 billion of unhedged variable rate debt outstanding would increase our annual interest expense by approximately $7 million.

## Controls and procedures

As filed, 2,344 characters.

a. Evaluation of Disclosure Controls and Procedures

Our management, including the principal executive officer and principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) related to the recording, processing, summarization and reporting of information in our reports that we file with the Securities and Exchange Commission as of September 30, 2016. These disclosure controls and procedures have been designed to provide reasonable assurance that material information relating to us, including our subsidiaries, is made known to our management, including these officers, by our employees, and that this information is recorded, processed, summarized, evaluated and reported, as applicable, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Based on their evaluation, as of September 30, 2016, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective.

b. Changes in Internal Control Over Financial Reporting

We acquired the following subsidiary during 2015:

- *Lake Region Medical Holdings, Inc.*

We believe that the internal controls and procedures of the above mentioned subsidiary are reasonably likely to materially affect our internal control over financial reporting. We are currently in the process of incorporating the internal controls and procedures of this subsidiary into our internal controls over financial reporting.

The Company is extending its Section 404 compliance program under the Sarbanes-Oxley Act of 2002 (the “Act”) and the applicable rules and regulations under such Act to include this subsidiary. However, the Company excluded this subsidiary from management’s assessment of the effectiveness of internal control over financial reporting as of January 1, 2016 as permitted by the guidance issued by the Office of the Chief Accountant of the Securities and Exchange Commission.

Other than as described above, there were no changes in the registrant’s internal control over financial reporting during our last fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 169 characters.

There have been no material changes to the Company’s risk factors as previously disclosed in the Company’s Annual Report on Form 10-K for the year ended January 1, 2016.

Filed Nov 8, 2016.
Source: SEC EDGAR, the filing index for accession 0001114483-16-000044. Last ingested by Listed: Nov 11, 2026, 00:08 ET. No prices; not investment advice.
